Spirometry system and disposable volume spirometry apparatus

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Stefano Soatto, , Giuseppe Torresin patent solves the following problem:

Measuring airflow and the number of regular made during clinical investigation in respiratory physiology and pathology, occupational medicine, sports medicine, allergy and immunology, respiratory function laboratory, pulmonology, as well as a variety of industrial and scientific state. Spirometry is a non-invasive approach to lung function testing that measures the amount (number) and / or speed (flow) of air that can be smoked out. Spirometry create measures that will help in assessing the situation such as asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, and other such lung-related conditions.

Our analysis of this patent is as follows:

Stefano Soatto, , Giuseppe Torresin’s patent US 9456768 B2 deals with Spirometry system and disposable volume spirometry apparatus.
A disposable number spirometry equipment and non-contact measuring systems are described. The spirometry system includes an expandable disposable number spirometry equipment, a remote non-contact sensor, memory, and a processor. The remote non-contact image sensor associated with the expandable disposable number spirometry apparatus. memory to store the captured images. processor operatively coupled to the memory and determines a number of expandable disposable number spirometry equipment by analyzing the captured images.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Device for selectively reducing absorption of unhealthy food

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Medibotics Llc patent solves the following problem:

Our analysis of this patent is as follows:

Medibotics Llc’s patent US 9456916 B2 deals with Device for selectively reducing absorption of unhealthy food.
This creation is a device and method for selectively and automatically reduced absorption of bad food in the gastrointestinal tract of a human, while allowing the normal absorption of healthy food. In one example, as a device comprising: a meat-recognition sensor; an absorption-reducing substance; an implanted reservoir; and a release-to-own mechanism that selectively and automatically News the substance into the human gastrointestinal tract when the sensor detects that the people consuming unhealthy food.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Surgical apparatus and structure for applying sprayable wound treatment material

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Covidien Lp patent solves the following problem:

The present disclosure relates to surgical instruments and methods for enhancing properties of tissue repaired or joined the surgical food and, especially in facilities and operations structure configured to use the mechanical surgical fasteners and / or a non- mechanical biocompatible wound treatment material to improve the properties of fixing or adjacent tissue at a target surgical site.

Our analysis of this patent is as follows:

Covidien Lp’s patent US 9456821 B2 deals with Surgical apparatus and structure for applying sprayable wound treatment material.
According to one aspect of the present disclosure, an apparatus for forming an anastomosis between adjacent tissue sections provided. apparatus includes a body portion; an actuation assembly operatively supported at a proximal end of the body; anvil assembly movably mounted on the distal end of the body portion for movement in and out of the body; an estimated congregation came between the body and the anvil assembly for moving the anvil into and out of the tubular body portion; a dispersion assembly operatively associated with the approximation assembly, the dispersion assembly including at least one angled surface defining at least one channel interposed between the anvil assembly and the body portion and configured to dispense a fluid; and at least one conduit for conducting wound treatment material dispersion assembly.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Polyethylene glycol-based dendrons

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Rutgers, The State University Of New Jersey patent solves the following problem:

Dendrimers (in Greek: dendri: wood-like and meros: about) monodisperse macromolecules with well-defined branched architecture and symmetrical morphology (Bosman, AW, chemicals Reviews 99, 1665-1688, (1999)). Dendrimers are contained in a series of branches out from an inner core. These branches are arranged in layers, called generations, and represents the repeating units (monomer) in a dendrimer. A typical dendrimer molecule contains an inner core, layers of repeating units, and many terminal functional groups. The active moieties be encapsulated into the core / cavity or attached to the surface of the dendrimers. The dendrimers differ from other nanocarriers that they possess a tunable structure, empty intramolecular pit, and multifunctional house faces (Duncan, R., Advanced Drug Delivery Reviews 57, 2215-2237, ( 2005)). The presence in that there is no room in the dendrimer, especially in the high generation dendrimers, may be the place for drug or gene material loading and transportation. Typically, payloads made within the dendrimer hole through covalent sense, hydrophobic interaction, hydrogen bonds, or bond interaction. The degradable or cleavable bonds such as Esther, imine, acetal and ketal preferred covalent bonding since they act as natural causes release response.

Our analysis of this patent is as follows:

Rutgers, The State University Of New Jersey’s patent US 9457099 B2 deals with Polyethylene glycol-based dendrons.
The instant invention relates to polyethylene glycol-based dendrons, if known PEGtide dendrons, its composition, and methods of use.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for inducing cell death in acute lymphoblastic leukemic system cells

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Cantargia Ab patent solves the following problem:

Chronic myeloid leukemia (CML) is the first human neoplasm associated with a recurrent genetic aberration; Philadelphia (Ph) chromosome, formed by a corresponding transition between chromosome 9 and 22, giving rise to a constitutively activated tyrosine kinase BCR / ABL11. In CML, Ph chromosome is believed to originate from a hematopoietic stem cell (HSC) as it clonally found in malignant myeloid cells and non-malignant lymphoid cells2. The Ph chromosome is found in a part of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). CML composed of heterogeneous cell in various stages maturation maintained by a small number of cells, called CML stem cells, sharing the capacity of self-renewal of normal HSC3 . This shows that CML stem cells at least partially resistant to current treatments tyrosine kinase inhibitors4,5, despite clinical success demonstrated a suppressive rather than curative effects of this disease. Therefore, recognition of a way to efficiently target CML stem cells very attractive to achieve a permanent cure for the disease. Such a strategy to identify a target in CML stem cells provide a novel means to eliminate CML stem cells. Encouraging reports its direction described in the related disorder acute myeloid leukemia (AML), where the antibody target CD123, CXCR4, CD44 or CD47 in AML stem cells to express anti-leukemic effects in animal AML models6-9. Furthermore, AML stem cell associated antigens CD96 and CLL-1 identified10,11, providing additional targeted candidates of this disease. Surprisingly, even in one of the most studied neoplasms of all time, called a cancer stem cell disorder, no cell surface biomarker so far recognized the CML that allows a future separation of CML stem cells in normal HSCs, when the rare CD34 + CD38 cell population12,13. Recognizing that a biomarker tool to characterize the CML stem cells, but can also be used for new treatment developments and for tracking therapeutic effects of ancient CML cells during treatment.

Our analysis of this patent is as follows:

Cantargia Ab’s patent US 9458237 B2 deals with Method for inducing cell death in acute lymphoblastic leukemic system cells.
The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and / or inhibiting the growth and / or proliferation pathological cells in the stem and / or progenitor cells associated with a neoplastic hematologic disorder, in which the cells expressing IL1RAP. A related aspect the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in identifying pathological stem cells and / or fathers cells associated with a neoplastic hematologic disorder, in which the cells expressing IL1RAP. Moreover given the medicine composition containing the agents to devise methods of using the same.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Temporarily stiffened mesh prostheses

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Tyrx, Inc. patent solves the following problem:

Artificial implants such as meshes, combined mesh products or other porous prostheses are often used to provide a physical barrier between tissue types or additional strength to a physical defects in soft tissue. However, such devices commonly associated with post-surgical complications including post-implant infection, pain, excessive scar formation and shrinkage of the prosthesis or mesh. Excessive scar formation, limited patient mobility, and chronic pain is often attributed to the size, shape, mass and implant a variety of efforts made to reduce the amount of permanent formation. For example, lighter meshes using smaller fibers, greater besieged, and / or larger size pore as he meshes woven from the -resorbable and resorbable material usage to solve these problems.

Our analysis of this patent is as follows:

Tyrx, Inc.’s patent US 9457129 B2 deals with Temporarily stiffened mesh prostheses.
The present invention relates to medical prostheses and methods of manufacturing the devices. In particular, the prostheses temporarily stiffened meshes with particular coatings provide initial hardness and thus allow easier surgical management for the treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that act as a hardening agent in the coat of filaments or fibers of the mesh in the temporary rise in points contact the filaments or fibers and / or by increasing the hardness of mesh at least 1.1 times its original hardness. In the minds of the invention may also provide relief from various post-operative complications associated with the implantation, insertion or surgical use. By including the biologically active agents and / or drugs in the coating, the devices provide Branch Tomato for relief and side effects or complications associated with the operation or use of prostheses generalized.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nutrition with non-viable Bifidobacterium and non-digestible oligosaccharide

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The N.V. Nutricia patent solves the following problem:

A human child is fed human milk develop after birth in an intestinal microbiota rich in lactic acid bacteria. This is due to the presence of non-digestible saccharides on human milk specifically fermented with lactic acid bacteria, particularly bifidobacteria.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9456629 B2 deals with Nutrition with non-viable Bifidobacterium and non-digestible oligosaccharide.
A child and / or child nutrition containing non-viable Bifidobacterium breve and a non-digestible oligosaccharide and its use revealed.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Process and device for forming a graphene layer

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Centre National De La Recherche Scientifique patent solves the following problem:

The present disclosure relates to a process and apparatus for forming graphene, and in particular to a process and apparatus for forming a graphene layer by chemical vapor deposition.

Our analysis of this patent is as follows:

Centre National De La Recherche Scientifique’s patent US 9458020 B2 deals with Process and device for forming a graphene layer.
the invention of a way to build a graphene layer that involves: heating a layer support in a reaction chamber; and build the graphene layer on a surface layer of support by: a) during a first period of time, introducing the reaction chamber in an organic compound gas to cause a form of carbon atoms on the surface; b) during a second period after the first period, a reduced rate of introduction of organic compound gas into the reaction chamber and introducing the reaction chamber with an additional gas, which further gas is a carbon etching gas; and repeated in a) and b) one or more times.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Gram-positive bacteria specific binding compounds

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genentech, Inc., , Aimm Therapeutics B.V. patent solves the following problem:

Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).

Our analysis of this patent is as follows:

Genentech, Inc., , Aimm Therapeutics B.V.’s patent US 9458228 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Combination therapy using c-Met inhibitor and c-Myc inhibitor

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Samsung Electronics Co., Ltd. patent solves the following problem:

If a method of preventing and / or treating a cancer, the method including the co-administration of a c-Met inhibitor and a c-Myc inhibitor to a subject in need thereof .

Our analysis of this patent is as follows:

Samsung Electronics Co., Ltd.’s patent US 9457043 B2 deals with Combination therapy using c-Met inhibitor and c-Myc inhibitor.
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a c-Myc inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of one-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of one-Myc inhibitor as an active ingredient, packaged together.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.